Table 1.
Demographic data and clinical characteristics in irritable bowel syndrome patients' groups before the start of the Mediterranean diet
|
Variable
|
Group I (Mediterranean diet) (n = 50)
|
Group II (n = 50)
|
P
value
|
| Age (yr) | 15.50 ± 1.80 | 15.2 ± 1.5 | 0.881 |
| Sex (M: F) | 27:23 | 26:24 | 0.902 |
| Height (z-score) | 0.04 ± 1 | 0.04 ± 1.00 | 0.661 |
| Weight (z-score) | 0.14 ± 0.99 | 0.12 ± 0.89 | 0.831 |
| BMI (z-score) | 0.18 ± 0.88 | 0.17 ± 1.02 | 0.771 |
| IBS subtypes | 0.472 | ||
| IBS-C | 22 (44 %) | 21 (42 %) | |
| IBS-D | 20 (40 %) | 21 (42 %) | |
| IBS-M | 4 (8 %) | 5 (10 %) | |
| IBS-U | 2 (4 %) | 3 (6 %) | |
| IBS severity | 0.552 | ||
| Mild | 12 (24%) | 14 (28 %) | |
| Moderate | 33 (66%) | 31 (62 %) | |
| Severe | 5 (10%) | 5 (10 %) | |
| Duration of IBS symptoms (mo) | 34.40 ± 9.10 | 35.30 ± 9.80 | 0.581 |
| Treatment drugs3 | 0.661 | ||
| Gastroprokinetic | 50 | 50 | |
| Antidepressants | 11 | 12 | |
| Antacids | 18 | 20 | |
| Antibioticsprobiotics | 924 | 723 | |
| IBS-SSS | 237.20 ± 65 | 248.30 ± 71.10 | 0.681 |
| IBS-QoL | 57.30 ± 12.90 | 59.10 ± 11.70 | 0.711 |
| Total score | 24.10 ± 10.40 | 22.80 ± 13.50 | 0.821 |
1
Independent t-test.
2
Chi-square test.
3
Treatment drugs for one month before starting the study and during the whole study period.
BMI: Body mass index; IBS: Irritable bowel syndrome; IBS-C: IBS constipation; IBS-D: IBS diarrhea; IBS-M: IBS mixed; IBS-U: IBS unsubtyped; IBS-SSS: IBS symptoms severity score questionnaire; IBS-QoL: IBS quality of life questionnaire.